Phase Ib/IIa Study for IPG11406 in Patients with Lupus Nephritis
Phase 1
Not yet recruiting
- Conditions
- Lupus Nephritis
- Interventions
- Drug: IPG11406
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT06717815
- Locations
- 🇨🇳
Nanjing DrumTower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Phase 1 Study for IPG11406 in Health Volunteer
Phase 1
Recruiting
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Drug: IPG11406
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 66
- Registration Number
- NCT06255834
- Locations
- 🇨🇳
Zhejiang Hospital, Hangzhou, Zhejiang, China
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Phase 1
Not yet recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: IPG1094
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06212076
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
A Study of Orally Administered IPG7236 in Healthy Adult Participants
Phase 1
- Conditions
- Atopic Dermatitis
- Interventions
- Other: Placebo (Part A)Drug: IPG7236- Single ascending doseDrug: IPG7236- Multiple ascending dose
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 86
- Registration Number
- NCT05288543
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- TolerabilitySafety IssuesPharmacokinetics
- Interventions
- Drug: IPG7236
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 196
- Registration Number
- NCT05142592
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇨🇳The First Affiliated Hospital Nanchang Univeristy, Nanchang, Jiangxi, China
🇨🇳Shandong Cancer Hospital, Jinan, Shangdong, China
Study of IPG1094 in Healthy Participants
Phase 1
- Conditions
- Safety Issues
- Interventions
- Drug: IPG1094Drug: placebo
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT05112159
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath